cancer - International Biopharmaceutical Industry

news

Allogene cleared by FDA to resume ‘off the shelf’ cancer cell therapy trials

The Food and Drug Administration has cleared Allogene Therapeutics to resume testing its cancer cell therapies after determining the company's technology wasn't to bl...

14 January 2022 news Allogene | cancer

Continue Reading →

news

Bristol Myers returns to Immatics for a dual-targeting cancer drug

Bristol Myers' acquisition of Celgene immediately made the big pharma a top player in the development of cancer cell therapies. Since the deal closed, Bristol Myers h...

15 December 2021 news Breyanzi | Bristol Myers

Continue Reading →

Volume 4 Issue 4

An End-to-End Solution to Accelerate CAR-T Cell Development from Concept to Clinic

CAR-T cell therapies have demonstrated tremendous success in relapsed or refractory haematological malignancies. Now therapeutics companies and academics alike are ra...

9 December 2021 Volume 4 Issue 4 cancer | CAR-T cell

Continue Reading →

Volume 4 Issue 4

Understanding the Role of Regulatory T Cells in Breast Cancer Metastasis

Breast cancer is the most common cancer amongst women accounting for 24 percent of new cancer cases worldwide and 15 percent of cancer deaths in 2018. While survival ...

9 December 2021 Volume 4 Issue 4 breast cancer | cancer

Continue Reading →

news

Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

Novartis' testing of canakinumab, which works by curbing inflammatory signaling in cells, for the seemingly unrelated use in lung cancer stems from an intriguing 2011...

29 October 2021 news cancer | cells

Continue Reading →

news

FDA halts tests of BioMarin drug amid heightened focus on gene therapy safety

The theoretical risk that gene therapy may cause cancer in humans has hung over the field for decades. Those worries resurfaced last year when a liver tumor was spott...

10 September 2021 news BioMarin | cancer

Continue Reading →

news

Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

Adaptimmune, like companies such as Bluebird Bio and Cellectis, remains one of the more prominent independent developers of cancer cell therapies. Early pioneers Kite...

10 September 2021 news Adaptimmune | Bluebird Bio

Continue Reading →

news

GSK, in race to catch up with rivals, wins expanded approval for cancer drug

GSK has high hopes for Jemperli as it transitions to what's being called the "new GSK," with a greater focus on experimental drugs for infectious disease, cancer and ...

20 August 2021 news Bristol Myers Squibb | cancer

Continue Reading →

news

How Bayer lured a biotech away from an IPO and into a buyout

In what has become a common move by large pharmaceutical companies attempting to revitalize their drug research, German healthcare conglomerate Bayer has acquired a s...

13 August 2021 news Bayer | Biotech

Continue Reading →

news

Immunotherapy advances spur new look at cancer vaccines

In an era of cancer immunotherapy, vaccines are getting fresh consideration as a therapeutic approach. Frustrated for years by lackluster results, cancer vaccine res...

29 June 2018 news advances | cancer

Continue Reading →